Is DMAA or DRDB more undervalued in 2026?

CirclFi compares Drugs Made In America Acquisiti (DMAA) and Roman DBDR Acquisition Corp. II (DRDB) using 13 institutional-grade valuation models. DMAA has a Quality of Company score of 5.0/10 while DRDB scores 4.5/10.

Which is a better buy — DMAA or DRDB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DMAA and DRDB valuations compare?

DMAA at $10.61 and DRDB at $10.52 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DMAA vs DRDB Valuation Comparison 2026 — Intrinsic Value Analysis

DMAA

Blank Checks

Drugs Made In America Acquisiti

Quality

5.0

out of 10

Value Trap

—

Price

$10.61

Last close

Models

11/13

Active

DRDB

Blank Checks

Roman DBDR Acquisition Corp. II

Quality

4.5

out of 10

Value Trap

—

Price

$10.52

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	DMAA Fair Value	DMAA Upside	DRDB Fair Value	DRDB Upside
Bayesian DCF	Intrinsic	$0.87	-91.8%	$1.29	-87.7%
Earnings Power Value	Intrinsic	$1.14	-89.3%	$1.39	-86.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DMAA vs DRDB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DMAA vs DRDB — Which Stock Is More Undervalued?

DMAA scores higher with a 5.0/10 quality rating vs DRDB's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Drugs Made In America Acquisiti (DMAA) and Roman DBDR Acquisition Corp. II (DRDB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DMAA currently trades at $10.61 with a QOC of 5.0/10, while DRDB trades at $10.52 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).